Shionogi & Co (JP:4507) has released an update.
Shionogi & Co. announces that its new drug application for the novel antibiotic cefiderocol has been accepted for review in China, signaling progress in the fight against drug-resistant infections. The drug, already available in over 10 countries, has shown superior efficacy in a Phase III trial in China for treating complicated urinary tract infections. Shionogi emphasizes its commitment to addressing infectious diseases globally, including AMR threats and the COVID-19 pandemic.
For further insights into JP:4507 stock, check out TipRanks’ Stock Analysis page.
